These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 37981892)
21. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. Tolomelli G; Mancuso K; Tacchetti P; Patriarca F; Galli M; Pantani L; Zannetti B; Motta MR; Rizzi S; Dan E; Sinigaglia B; Giudice V; Olmo A; Arpinati M; Chirumbolo G; Fanin R; Lewis RE; Paris L; Bonifazi F; Cavo M; Curti A; Lemoli RM Bone Marrow Transplant; 2020 May; 55(5):946-954. PubMed ID: 31768009 [TBL] [Abstract][Full Text] [Related]
22. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194 [TBL] [Abstract][Full Text] [Related]
23. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180 [TBL] [Abstract][Full Text] [Related]
24. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Johnsrud A; Ladha A; Muffly L; Shiraz P; Goldstein G; Osgood V; Shizuru JA; Johnston L; Arai S; Weng WK; Lowsky R; Rezvani AR; Meyer EH; Frank MJ; Negrin RS; Miklos DB; Sidana S Transplant Cell Ther; 2021 Jul; 27(7):590.e1-590.e8. PubMed ID: 33915323 [TBL] [Abstract][Full Text] [Related]
25. Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use. Jantunen E; Varmavuo V; Juutilainen A; Kuittinen T; Mahlamäki E; Mäntymaa P; Nousiainen T Ann Hematol; 2012 Jul; 91(7):1073-9. PubMed ID: 22302373 [TBL] [Abstract][Full Text] [Related]
26. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198 [TBL] [Abstract][Full Text] [Related]
32. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. DiPersio JF; Micallef IN; Stiff PJ; Bolwell BJ; Maziarz RT; Jacobsen E; Nademanee A; McCarty J; Bridger G; Calandra G; J Clin Oncol; 2009 Oct; 27(28):4767-73. PubMed ID: 19720922 [TBL] [Abstract][Full Text] [Related]
33. Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era. Rybinski B; Rapoport AP; Badros AZ; Hardy N; Kocoglu M Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e716-e729. PubMed ID: 35504807 [TBL] [Abstract][Full Text] [Related]
34. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277 [TBL] [Abstract][Full Text] [Related]
35. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Kim JS; Yoon DH; Park S; Yoon SS; Cho SG; Min CK; Lee JJ; Yang DH; Kwak JY; Eom HS; Kim WS; Kim H; Do YR; Moon JH; Lee J; Suh C Ann Hematol; 2016 Mar; 95(4):603-11. PubMed ID: 26754633 [TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. Micallef IN; Stiff PJ; Stadtmauer EA; Bolwell BJ; Nademanee AP; Maziarz RT; Partisano AM; Marulkar S; DiPersio JF Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769 [TBL] [Abstract][Full Text] [Related]
37. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost. Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430 [TBL] [Abstract][Full Text] [Related]
38. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization. Portuguese AJ; Yeh AC; Banerjee R; Holmberg L; Wuliji N; Green DJ; Mielcarek M; Gopal AK; Gooley T; Stevenson P; Cowan AJ Transplant Cell Ther; 2024 Aug; 30(8):774.e1-774.e12. PubMed ID: 38768908 [TBL] [Abstract][Full Text] [Related]
39. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience. Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation. Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]